Elotuzumab Market | Contrive Datum Insights

The Global Elotuzumab Market Is Expected To Grow From USD 1.8 Billion In 2020 To 2030, At A CAGR Of 3% During The Forecast Period (2021-2030).

Elotuzumab Market Overview:

Increasing number of cancer patients and growing awareness of cancer treatment are some of the factors driving the growth of this market.Elotuzumab is a monoclonal antibody that was approved by the FDA in 2015 for the treatment of multiple myeloma. It acts as an immunomodulator and targets growth factor receptor binding protein 11 (GRB11). It is a drug used in combination with lenalidomide and dexamethasone to treat multiple myeloma. Elotuzumab is sold under the brand name Empliciti by the Bristol-Myers Squibb Company.

Elotuzumab market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (million USD), with historical and forecast data for the period 2017 to 2030, with 2022 being considered as the base year. This report segments the global Elotuzumab market in detail. Regional market sizes related to products by type, by application, and by the player are also delivered. In estimating the size of the market, we took into account the impact of COVID-19 and the Russian-Ukraine war.

Major Segments Covered in the Global Elotuzumab Market:

Market Key Players:
Bristol Myers Squibb, Abbvie, And Others.

Elotuzumab Market by Types:

• 300mg Injection, 400mg Injection

Elotuzumab Market by Applications:

• Hospital, Clinic, Drug Center, Other

Elotuzumab Market by Regions:

The report estimates revenue growth at the worldwide, regional, and country levels and delivers an analysis of the recent industry trends in each sub-segment from 2017 to 2030.

Asia Pacific is expected to be the fastest growing market for elotuzumab during the forecast period. The high growth in the region can be attributed to rising prevalence of blood disorders, increasing geriatric population base, and increasing government initiatives to provide healthcare facilities.

North America is expected to be the second fastest growing market for elotuzumab during the forecast period. Rising prevalence of blood disorders and government initiatives in North America are driving the growth of this market.

Europe accounted for a large share of the global elotuzumab market owing to increasing geriatric population base, rising number of cancer cases, and availability of advanced healthcare infrastructure.

• North America
• US
• Canada
• Mexico
• Rest of North America
• Europe
• Germany
• France
• Italy
• Spain
• UK
• Nordic Countries
• Denmark
• Finland
• Iceland
• Sweden
• Norway
• Benelux Union
• Belgium
• The Netherlands
• Luxembourg
• Rest of Europe
• Asia-Pacific
• Japan
• China
• India
• Australia
• South Korea
• Southeast Asia
• Indonesia
• Thailand
• Malaysia
• Singapore
• Rest of Southeast Asia
• Rest of Asia-Pacific
• The Middle East & Africa
• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest of the Middle East & Africa
• Latin America
• Brazil
• Argentina
• Rest of Latin America

Significant Market Dynamics:

Growth Factors:

The global elotuzumab market is expected to reach USD 18.361 billion by 2021. The growth of the market can be attributed to rising cases of multiple myeloma (MM) and growing R&D in the biopharmaceutical industry. Moreover, increasing number of product development collaboration agreements between manufacturers and researchers is also a driving factor for the elotuzumab market. Moreover, increasing geriatric population in North America and Europe will further drive the elotuzumab market over the forecast period 2019-2030. Moreover, stringent regulations on reimbursement policies by governments of various countries will further limit the use of potential patients in hospitals and clinics, leading to a decrease in the number of clinical trials conducted by researchers in the coming years, which may affect the global elotuzumab market size from 2021 onwards.

Report Scope of Global Elotuzumab Market:

Points Covered in the Report

• The points that are discussed within the report are the major market players that are involved in the Market such as Market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.
• The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analyzed 12 years of data history and forecast.
• The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail.
• Data and information by market player, region, type, application and etc., and custom research can be added according to specific requirements.
• The report contains a SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Frequently Asked Questions-

What is the CAGR of Elotuzumab market?

The Elotuzumab Market is growing at a CAGR of 3% During Forecast Period.

 What are the key types and applications of Elotuzumab market?

- 300mg Injection, 400mg Injection

- Hospital, Clinic, Drug Center, Other

Who are the key players in Elotuzumab market?

Bristol Myers Squibb, Abbvie, And others.

Any special requirements about this report, please let us know and we can provide custom report.

Note – In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19 and the Russia-Ukraine war.